Sign In
Buy PHAT
$10.09
+0.440 (+4.56%)
At Close: Jun 03, 2026
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Monday, 23'rd Jun 2025
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
07:59am, Monday, 23'rd Jun 2025
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy
10:08am, Tuesday, 10'th Jun 2025
I'm bullish on Phathom Pharmaceuticals, Inc. after the FDA granted 10-year exclusivity to their flagship GI drug, Voquezna, giving them near-monopoly status. For those who don't know, this is a big de
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade
11:01am, Monday, 09'th Jun 2025
The consensus price target hints at a 107.4% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e
Phathom Pharmaceuticals price target raised by $6 at Cantor Fitzgerald, here's why
01:05pm, Friday, 06'th Jun 2025
19 Aug
FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petit
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
07:59am, Thursday, 15'th May 2025
FLORHAM PARK, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointe
After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)
10:35am, Thursday, 08'th May 2025
Phathom Pharmaceuticals (PHAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analys
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Thursday, 01'st May 2025
FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointe
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript
12:09pm, Thursday, 01'st May 2025
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
09:20am, Thursday, 01'st May 2025
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.42 per share a year ago.
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
07:00am, Thursday, 01'st May 2025
VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providers Net revenues of $28.5 million reported for Q1 Filled VOQUEZNA prescr
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting
07:59am, Monday, 28'th Apr 2025
FLORHAM PARK, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025
08:00am, Wednesday, 23'rd Apr 2025
• Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical
